FQ
NKTR icon

First Quadrant’s Nektar Therapeutics NKTR Stock Holding History

First Quadrant’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,940
Closed -$1.57M – 646
2019
Q2 		$1.57M Buy
2,940
+2,382
+427% +$1.19M 0.11% 220
2019
Q1 		$281K Buy
558
+538
+2,690% +$319K 0.02% 448
2018
Q4 		$10K Buy
+20
New +$12.1K ﹤0.01% 786

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Quadrant's NKTR Position: Q3 2019 in Review

First Quadrant sold out of Nektar Therapeutics (NKTR) in Q3 2019, closing a stake of 2,940 shares — an estimated $1.57M sold.

First Quadrant first reported a position in NKTR in Q4 2018 and held it in 3 quarters. The position peaked at $1.57M in Q2 2019. 288 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

  • First Quadrant reported no remaining Nektar Therapeutics position as of Q3 2019 after selling out during the quarter.
  • First Quadrant sold 2,940 Nektar Therapeutics shares in Q3 2019, an estimated $1.57M.
  • First Quadrant first reported a position in Nektar Therapeutics in Q4 2018 and held it in 3 quarters.
  • First Quadrant's Nektar Therapeutics position peaked at $1.57M in Q2 2019.
  • 288 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on First Quadrant's 13F filing for Q3 2019, filed 25 Oct 2019.